CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

CVM 1.84 +0.03 (1.82%)
price chart
Cel-Sci Corporation: The Arbitration Is On, But Is The Phase III Trial Off?
I've gone through fur or five significant redrafts of this article since I started trying to get it organized at the end of August, and each time I thought I had captured a good representation of the current situation for Cel-Sci Corp. (NYSEMKT:CVM ...
A Closer Look At Cel-Sci Corporation Going Into Spring Of 2016
Cel-Sci Corporation (NYSEMKT:CVM) is on the verge of several significant milestones and inflection points during the first several months of 2016.
CEL-SCI Corporation Releases Letter to Shareholders
Our Phase 3 study in advanced primary (untreated) head and neck cancer patients with the investigational drug Multikine* (Leukocyte Interleukin Inj.
CEL-SCI Announces Reverse Stock Split
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.
CEL-SCI Corp.
CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head and neck cancer study. CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head and neck cancer study.
Analyst's Hold rated Stock: CEL-SCI Corporation (CVM)
CEL-SCI Corporation (CVM) stock price traded with surging change along with the volume 0.09 million shares in Friday trading session.
What's Transpiring With Shares of CEL-SCI Corporation (AMEX:CVM)?  Financial Newsweek
Cel Sci Corporation (NYSEAMERICAN:CVM) Just Reported Decreased Shorts  Weekly Register
CEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure
On June 28, 2017 CEL-SCI Corporation received a letter from the U.S. Food and Drug Administration (FDA) in response to CEL-SCI's most recent June 2, 2017 submission regarding the clinical hold imposed on the Company's Phase 3 head and neck cancer study ...
Vienna's Cel-Sci Corp. raises $1 million for head and neck cancer trial
Cel-Sci, led by CEO Geert Kersten, has said it spent more than a decade and $80 million in developing and validating the manufacturing process for Multikine.
CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to March 1, 2018 (close of business).
CEL-SCI Corporation (NYSEMKT:CVM): What Is Price Telling Us?
CEL-SCI Corporation (NYSEMKT:CVM) has had a noteworthy run year to date. The company started out 2017 at around $0.07 a share, and has since gained to trade above $0.11 - a 60% gain across the period.
The Saga Of CEL-SCI Corporation (NYSEMKT:CVM)'S Bleak Clinical Trials  Journal Transcript